A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Orantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ORIENTAL
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 31 Jul 2014 Trial terminated after interim analysis by an independent data monitoring committee found pre-determined standard related to the primary endpoint of overall survival was not met, according to a Taiho Pharmaceutical media release.
    • 31 Jul 2014 Primary endpoint (Overall survival) has not been met, according to a Taiho Pharmaceutical media release.
    • 31 Jul 2014 Status changed from active, no longer recruiting to discontinued, according to a Taiho Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top